Global Hepatocellular Carcinoma Market - 2023-2030

Global Hepatocellular Carcinoma Market - 2023-2030

The Global Hepatocellular Carcinoma Market reached US$ 977 million in 2022 and is expected to reach US$ 2.4 billion by 2030 and grow with a CAGR of 12.2% during the forecast period 2023-2030. The hepatocellular carcinoma market trends show a large pipeline for hepatocellular carcinoma owing to the rising clinical trials and increasing research and development.

The hepatocellular carcinoma (HCC) market of intrahepatic bile duct has increased the market share for hepatocellular carcinoma. For instance, the American Cancer Society predicted that by the end of 2022, primary liver or intrahepatic bile duct cancer would account for roughly 41,260 new diagnosis cases and around 30,520 fatalities.

The global market for hepatocellular carcinoma is expanding due to factors including the increasing efforts for early and proper diagnosis of HCC, the growing size of the therapeutic pipeline, and high research and development. On August 17, 2022, Bristol Myers Squibb acquired Turning Point Therapeutics, expanding its precision oncology portfolio.

Market Dynamics

Growing Efforts for Early Diagnosis of HCC drive the growth of the Hepatocellular Carcinoma market.

A few clinical trials are currently being conducted to determine the best method for diagnosing hepatocellular carcinomas. These include studies to assess the diagnostic performance of contrast-enhanced ultrasound (CEUS) and gadoxetic acid-enhanced liver MRI among individuals with liver cirrhosis, as well as a multicenter, prospective comparison research of multiphase contrast-enhanced MRI and CT for the detection of hepatocellular carcinoma and liver transplant recipients.

Researchers must further define cost, generalizability, or application logistics for implementation in patient care because newer diagnostic techniques like NGS/biomarkers, molecular imaging, liquid biopsy, and artificial intelligence remain in their early stages. This is in addition to identifying appropriate genes, targets, or techniques. To identify the advantages and restrictions of each strategy when compared to one another and best practice, multi-center prospective studies are required.

Rising Technological Advancements and Clinical Trials creates lucrative opportunities for manufacturers

Various research and clinical trials are being conducted by the major key players in collaboration or partnership, showing positive outcomes. For instance, on January 18, 2022, the anti-PD-1 drug KEYTRUDA and best supportive care (BSC) were investigated in Phase 3 KEYNOTE-394 trial, which was conducted in patients with advanced forms of hepatocellular carcinoma (HCC) who had previously received sorafenib treatment in Asia.

For people previously treated for advanced HCC, KEYTRUDA plus BSC reduced the risk of mortality by 21% compared to placebo plus BSC. This improvement in OS was statistically noteworthy and clinically meaningful. With a worldwide advancement program of seven clinical studies that have included or are anticipated to enroll over 3,000 patients, Merck is committed to furthering research in HCC.

The Lack of Diagnosis Methods and Treatment Side Effects will Hamper the Growth of the Market.

However, the global marketplace for hepatocellular carcinoma may be constrained over the projected period due to the unavailability of proper treatment and various side effects associated with treatment. Because symptoms and signs of liver cancer frequently do not manifest until it is advanced, it can be challenging to detect it early. Because the right rib cage covers most of the liver, small liver tumors can be difficult to find during a physical examination.

Some targeted treatments prevent cancers from growing new blood vessels. Others go after specific cancer cell proteins that promote tumor growth. Fatigue, rash, decreased appetite, diarrhea, soreness, bleeding, scorching of the hands or feet, and holes in the intestine and stomach are only possible side effects.

COVID-19 Impact Analysis

The COVID-19 Analysis considers the Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario in addition to Pricing Dynamics, Demand-Supply Spectrum, Government Initiatives, and Manufacturers’ Strategic Initiatives. These factors could cause supply and demand to shift due to trading restrictions, lockdowns, and after-effects issues.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global hepatocellular carcinoma market, owing to the low number of key market players in this region. However, the effect of the import and export of raw materials is expected to have little influence over the global hepatocellular carcinoma market growth over the forecast period.

Segment Analysis

The Global Hepatocellular Carcinoma Market is segmented based on treatment type, end user and region.

Owing to Adoption, the Chemotherapy Segment Accounted for Approximately 36.7% of the Hepatocellular Carcinoma Market Share

The chemotherapy segment led the market for hepatocellular carcinoma, and this trend is expected to continue over the projected period 2023-2030. According to clinicaltrials.gov, 18 studies are ongoing and anticipated to be finished during the forecast period.

A few examples include a Phase 3 study sponsored by Sun Yat-sen University to assess the safety and efficacy of Sorafenib in combination with hepatic arterial infusion chemotherapy in comparison with the transarterial chemoembolization combined with Sorafenib in patients having BCLC C stage hepatocellular carcinoma.

A study on the safety and effectiveness of the treatment, Tislelizumab in combination with hyperthermic intraperitoneal chemotherapy and targeted therapy, which is utilized for hepatocellular carcinoma with high-risk, after R0 resection sponsored by the Hunan Provincial People's Hospital and is estimated to be completed by July 2025.

Geographical Analysis

North America Accounted for Approximately 37.2% of the Market Share, Owing to the Strong Presence of Major Players And Increasing Technological Advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for hepatocellular carcinoma for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of carcinoma therapeutics, increasing demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, fueling the demand of hepatocellular carcinoma diagnostics and treatment.

Rising new product launches for use in patients with carcinoma will drive market growth. Growth is also fueled by increasing technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various treatment approaches for hepatocellular carcinomas, such as biomarkers, leading to the market expansion in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the hepatocellular carcinoma market include Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol Myers Squibb, Bayer AG, Polaris Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Harbour BioMed, Creative Diagnostics and Merck & Co. Inc. among others.

Why Purchase the Report?
• To visualize the Global Hepatocellular Carcinoma Market segmentation based on treatment type, end user and region, and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous hepatocellular carcinoma market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Hepatocellular Carcinoma Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies